S&P 500   3,331.80 (-0.59%)
DOW   27,382.48 (-0.73%)
QQQ   276.45 (-0.27%)
AAPL   114.05 (-0.79%)
MSFT   208.17 (-0.61%)
FB   259.33 (+0.98%)
GOOGL   1,461.39 (+0.19%)
AMZN   3,164.87 (-0.29%)
TSLA   425.73 (+1.08%)
NVDA   526.39 (+0.96%)
BABA   278.07 (+0.75%)
CGC   14.54 (+2.32%)
MU   50.57 (+1.71%)
GE   6.09 (-1.77%)
AMD   81.34 (+2.34%)
T   28.19 (-0.67%)
F   6.57 (-1.79%)
ACB   4.93 (+3.14%)
GILD   62.15 (-1.11%)
NFLX   490.82 (+0.03%)
DIS   124.14 (-1.47%)
BA   163.07 (-1.81%)
BAC   23.58 (-2.12%)
S&P 500   3,331.80 (-0.59%)
DOW   27,382.48 (-0.73%)
QQQ   276.45 (-0.27%)
AAPL   114.05 (-0.79%)
MSFT   208.17 (-0.61%)
FB   259.33 (+0.98%)
GOOGL   1,461.39 (+0.19%)
AMZN   3,164.87 (-0.29%)
TSLA   425.73 (+1.08%)
NVDA   526.39 (+0.96%)
BABA   278.07 (+0.75%)
CGC   14.54 (+2.32%)
MU   50.57 (+1.71%)
GE   6.09 (-1.77%)
AMD   81.34 (+2.34%)
T   28.19 (-0.67%)
F   6.57 (-1.79%)
ACB   4.93 (+3.14%)
GILD   62.15 (-1.11%)
NFLX   490.82 (+0.03%)
DIS   124.14 (-1.47%)
BA   163.07 (-1.81%)
BAC   23.58 (-2.12%)
S&P 500   3,331.80 (-0.59%)
DOW   27,382.48 (-0.73%)
QQQ   276.45 (-0.27%)
AAPL   114.05 (-0.79%)
MSFT   208.17 (-0.61%)
FB   259.33 (+0.98%)
GOOGL   1,461.39 (+0.19%)
AMZN   3,164.87 (-0.29%)
TSLA   425.73 (+1.08%)
NVDA   526.39 (+0.96%)
BABA   278.07 (+0.75%)
CGC   14.54 (+2.32%)
MU   50.57 (+1.71%)
GE   6.09 (-1.77%)
AMD   81.34 (+2.34%)
T   28.19 (-0.67%)
F   6.57 (-1.79%)
ACB   4.93 (+3.14%)
GILD   62.15 (-1.11%)
NFLX   490.82 (+0.03%)
DIS   124.14 (-1.47%)
BA   163.07 (-1.81%)
BAC   23.58 (-2.12%)
S&P 500   3,331.80 (-0.59%)
DOW   27,382.48 (-0.73%)
QQQ   276.45 (-0.27%)
AAPL   114.05 (-0.79%)
MSFT   208.17 (-0.61%)
FB   259.33 (+0.98%)
GOOGL   1,461.39 (+0.19%)
AMZN   3,164.87 (-0.29%)
TSLA   425.73 (+1.08%)
NVDA   526.39 (+0.96%)
BABA   278.07 (+0.75%)
CGC   14.54 (+2.32%)
MU   50.57 (+1.71%)
GE   6.09 (-1.77%)
AMD   81.34 (+2.34%)
T   28.19 (-0.67%)
F   6.57 (-1.79%)
ACB   4.93 (+3.14%)
GILD   62.15 (-1.11%)
NFLX   490.82 (+0.03%)
DIS   124.14 (-1.47%)
BA   163.07 (-1.81%)
BAC   23.58 (-2.12%)
Log in
NASDAQ:AKBA

Akebia Therapeutics Stock Forecast, Price & News

$2.41
-0.03 (-1.23 %)
(As of 09/29/2020 11:58 AM ET)
Add
Compare
Today's Range
$2.39
Now: $2.41
$2.48
50-Day Range
$2.46
MA: $6.49
$10.98
52-Week Range
$2.34
Now: $2.41
$13.71
Volume50,969 shs
Average Volume2.69 million shs
Market Capitalization$345.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
Akebia Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$335 million
Book Value$3.32 per share

Profitability

Net Income$-279,660,000.00
Net Margins-113.35%

Miscellaneous

Employees324
Market Cap$345.39 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$2.41
-0.03 (-1.23 %)
(As of 09/29/2020 11:58 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

How has Akebia Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AKBA stock has decreased by 65.3% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Akebia Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akebia Therapeutics
.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Akebia Therapeutics
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.02. The biopharmaceutical company earned $90.14 million during the quarter, compared to the consensus estimate of $76.24 million. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%.
View Akebia Therapeutics' earnings history
.

What price target have analysts set for AKBA?

7 brokers have issued 1 year price objectives for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Akebia Therapeutics' stock price to reach $10.43 in the next twelve months. This suggests a possible upside of 332.7% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 9,170,000 shares, an increase of 12.4% from the August 31st total of 8,160,000 shares. Based on an average daily volume of 4,620,000 shares, the days-to-cover ratio is currently 2.0 days.
View Akebia Therapeutics' Short Interest
.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), TherapeuticsMD (TXMD), NVIDIA (NVDA), Opko Health (OPK), Pfizer (PFE) and Advanced Micro Devices (AMD).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
  • Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $2.41.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $345.39 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is www.akebia.com.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.